Funding for this research was provided by:
Received: 26 May 2021
Accepted: 11 March 2022
First Online: 21 March 2022
: As the ATLAS program does not require any additional tests, expenses, or procedures on behalf of the patient outside of normal patient care and no patient identifiers are collected ethical approval was not required.
: Each participating Investigator/Institution was required to sign a participation agreement that gave explicit rights allowing the submitted organisms to be included in ATLAS and confirming acceptance that the data may be used for publication.
: GGS is an employee of Pfizer Inc. and a Pfizer Inc. shareholder. MAH is an employee of IHMA and has no personal financial interests in the sponsor of the study (Pfizer, Inc.).